Liminatus Pharma, Inc. - LIMN

Sector: Healthcare · Industry: Biological Products, (No Diagnostic Substances)
Website: No information yet · Social: No information yet

Company profile

Powered by TradingView

Quarter snapshot

Latest / Compare
Q4 2025 · Q3 2025
Value (USD)
Total reported value ($000)
$189K
QoQ value delta ($000)
-$245K (-56.45%)
Implied price effect (QoQ)
-64.04%
Shares
Total shares
317,193
QoQ shares delta
+55,269 (+21.1%)
Total shares held by funds (by quarter)
Shares (left)

Fund holders include prior positions carried forward until a new 13F confirms a change. Reported holders have reported a position in this security for that quarter; this is not the total number of 13F filers.

Market chart (LIMN)

Powered by TradingView
Interactive chart by TradingView.

Top holders (Q4 2025)

Top 25 only Full list
Early Q2 2026 data: only 14 institutional holders reported so far. More will appear as funds file with the SEC.
Manager Value ($000) Shares % of 13F
VANGUARD GROUP INC 44 73,424 0.0%
CITADEL ADVISORS LLC 43 70,930 0.0%
GEODE CAPITAL MANAGEMENT, LLC 39 65,051 0.0%
TWO SIGMA INVESTMENTS, LP 21 35,284 0.0%
STATE STREET CORP 11 19,000 0.0%
UBS Group AG 11 19,395 0.0%
BlackRock, Inc. 8 13,255 0.0%
TWO SIGMA SECURITIES, LLC 7 11,875 0.0%
Tower Research Capital LLC (TRC) 5 8,903 0.0%
BANK OF AMERICA CORP /DE/ 0 44 0.0%
CITIGROUP INC 0 1 0.0%
Farther Finance Advisors, LLC 0 31 0.0%